SCHEMBL1719191

SCHEMBL1719191

CC(C)(C)c1ccc2c(c1)Sc1ccccc1N2

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX1 Q9Y5S8 11/20 0.62
CYBB P04839 2/20 0.61
NOX3 Q9HBY0 2/20 0.61
NOX4 Q9NPH5 2/20 0.61
MAPT P10636 7/20 0.59
GAA P10253 6/20 0.59
SNCA P37840 4/20 0.59
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
ALOX15 P16050 3/20 0.59
TDP1 Q9NUW8 2/20 0.59
BCHE P06276 2/20 0.59
ACHE P22303 2/20 0.59
CYP1A2 P05177 2/20 0.59
POLB P06746 1/20 0.59
CYP3A4 P08684 1/20 0.59
ADORA3 P0DMS8 1/20 0.59
ALOX12 P18054 1/20 0.59
MAOA P21397 1/20 0.59
CNR1 P21554 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20664930 0.91 SNCA (0.50) NOX1CYBBNOX3NOX4MAPT
SCHEMBL30336020 0.91 SNCA (0.50) NOX1CYBBNOX3NOX4MAPT
SCHEMBL25898787 0.90 NOX1 (0.71) NOX1CYBBNOX3NOX4MAPT
SCHEMBL28110666 0.88 NOX1 (0.58) NOX1CYBBNOX3NOX4MAPT
SCHEMBL885158 0.85 NOX1 (0.57) NOX1CYBBNOX3NOX4MAPT
SCHEMBL30811565 0.84 NOX1 (0.84) NOX1CYBBNOX3NOX4MAPT
SCHEMBL10372692 0.84 NOX1 (0.84) NOX1CYBBNOX3NOX4MAPT
SCHEMBL1718166 0.84 NOX1 (0.55) NOX1CYBBNOX3NOX4MAPT
Phenothiazine SCHEMBL4288768 0.84 ALOX15 (0.58) NOX1CYBBNOX3NOX4MAPT
SCHEMBL1718554 0.83 NOX1 (0.54) NOX1CYBBNOX3NOX4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2998303-B1 PHENOTHIAZINE DERIVATIVES AND METHODS FOR TREATING TUMORS B & G PARTNERS LLC (US) 2018-06-13 EP disclosed
EP-2998303-A1 PHENOTHIAZINE DERIVATIVES AND METHODS FOR TREATING TUMORS B & G Partners, LLC (US) 2016-03-23 EP disclosed
US-9198916-B1 Compounds and methods for treating tumors B&G PARTNERS, LLC (US) 2015-12-01 US disclosed
US-8148565-B2 Method of manufacturing an organic silicon compound that contains a methacryloxy group or an acryloxy group DOW CORNING TORAY COMPANY, LTD. (JP) 2012-04-03 US disclosed
EP-1915384-B1 A METHOD OF MANUFACTURING AN ORGANIC SILICON COMPOUND THAT CONTAINS A METHACRYLOXY GROUP OR AN ACRYLOXY GROUP DOW CORNING TORAY CO LTD (JP) 2012-01-11 EP disclosed
US-20090306370-A1 Method Of Manufacturing An Organic Silicon Compound That Contains A Methacryloxy Group Or An Acryloxy Group DOW TORAY CO., LTD. (JP) 2009-12-10 US disclosed
EP-1915384-A1 A METHOD OF MANUFACTURING AN ORGANIC SILICON COMPOUND THAT CONTAINS A METHACRYLOXY GROUP OR AN ACRYLOXY GROUP Dow Corning Toray Co., Ltd. (JP) 2008-04-30 EP disclosed
WO-2007020932-A1 A METHOD OF MANUFACTURING AN ORGANIC SILICON COMPOUND THAT CONTAINS A METHACRYLOXY GROUP OR AN ACRYLOXY GROUP DOW CORNING TORAY CO., LTD. (JP) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306370-A1 Method Of Manufacturing An Organic Silicon Compound That Contains A Methacryloxy Group Or An Acryloxy Group SIK1, SMS, SIK2 NOX1 3375/4885CYBB 3891/4885NOX3 3092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.